Acalabrutinib (Acalabrutinib) effects and efficacy

Acalabrutinib is a small molecule inhibitor of BTK. Acalabrutinib is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy and for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

After a median follow-up of more than 4 years, 86% of patients remained on treatment, suggesting high efficacy (a 97% response rate, including 7 %complete response)and acceptable tolerability, 5% of patients developed atrial fibrillation, 22% developed hypertension. The 36month progression-free survival rate in the acalabrutinib group was 61%, whileidela lisib/rituximab or bendamustine/The rituximab group was 17%. Median overall survival was not reached in either group. At 36 months, the overall survival rate for patients in the acalabrutinib group was 80%.

As long asacalabrutinibis effective forthe patientand any side effects are manageable,patientsusually continue to take it. Do not stop taking acalabrutinib without talking to your doctor.

Acalabrutinib is a small molecule inhibitor of BTK. Acalabrutiniband its active metabolite ACP-5862 form covalent bonds with the cysteine u200bu200bresidues in the BTK active site, resulting in the inhibition of BTK enzyme activity. BTKis a signaling molecule for the Bcell antigen receptor(BCR) and cytokine receptor pathways. In B cells, BTKSignaling results in the activation of B pathways necessary for cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, acalabrutinib inhibits BTK-mediated activation of downstream signaling proteins CD86 and CD69 and suppresses malignant B cell proliferation and tumor growth in mouse xenograft models. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0